drug_name event_name drug_id event_id drug_and_event_name
3 Chlorthalidone Chronic bronchitis 1395058 255841 Chlorthalidone & Chronic bronchitis 
## Chronograph ##

## Basic demographioc table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 117 100 Total 1000 100 Total 731 100 Total 1000 100
Sex gender = FEMALE 65 56 Sex gender = FEMALE 593 59 Sex gender = FEMALE 406 56 Sex gender = FEMALE 576 58
gender = MALE 52 44 gender = MALE 407 41 gender = MALE 325 44 gender = MALE 424 42
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 0 0 (20,30] 3 0 (20,30] 4 1 (20,30] 10 1
(30,40] 6 5 (30,40] 29 3 (30,40] 13 2 (30,40] 21 2
(40,50] 4 3 (40,50] 41 4 (40,50] 31 4 (40,50] 27 3
(50,60] 12 10 (50,60] 72 7 (50,60] 32 4 (50,60] 56 6
(60,70] 28 24 (60,70] 232 23 (60,70] 164 22 (60,70] 247 25
(70,80] 40 34 (70,80] 337 34 (70,80] 249 34 (70,80] 361 36
(80,90] 21 18 (80,90] 225 22 (80,90] 192 26 (80,90] 231 23
(90,110] 6 5 (90,110] 61 6 (90,110] 46 6 (90,110] 47 5
Median 72 IQR=(66, 80) Median 74 IQR=(68, 82) Median 75 IQR=(68, 83) Median 74 IQR=(68, 82) 
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 117) % (n = 1,000) Std.Diff Characteristic % (n = 117) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 2.6 1.4 -0.08
25 - 29 0 0.3 0.08 Visual system disorder 46.2 36.6 -0.19
30 - 34 0.9 0.7 -0.02 Medical history: Cardiovascular disease
35 - 39 4.3 1.7 -0.15 Atrial fibrillation 41.9 26.6 -0.33
40 - 44 0.9 1.7 0.08 Cerebrovascular disease 17.1 10.0 -0.21
45 - 49 2.6 2.4 -0.01 Coronary arteriosclerosis 45.3 30.4 -0.31
50 - 54 3.4 3.5 0.00 Heart disease 82.9 56.9 -0.59
55 - 59 4.3 3.6 -0.03 Heart failure 44.4 24.5 -0.43
60 - 64 5.1 3.9 -0.06 Ischemic heart disease 16.2 13.5 -0.08
65 - 69 17.1 15.4 -0.05 Peripheral vascular disease 42.7 26.2 -0.35
70 - 74 17.1 17.4 0.01 Pulmonary embolism 3.4 2.8 -0.04
75 - 79 17.1 17.4 0.01 Venous thrombosis 9.4 6.6 -0.10
80 - 84 12.0 14.1 0.06 Medical history: Neoplasms
85 - 89 10.3 10.2 0.00 Hematologic neoplasm 9.4 7.2 -0.08
90 - 94 1.7 4.5 0.16 Malignant lymphoma 5.1 2.9 -0.11
95 - 99 3.4 2.3 -0.07 Malignant neoplasm of anorectum 0.9 1.1 0.02
100 - 104 0 0.9 0.13 Malignant neoplastic disease 40.2 26.0 -0.30
Gender: female 55.6 59.3 0.08 Malignant tumor of breast 6.8 3.9 -0.13
Medical history: General Malignant tumor of colon 6.8 2.6 -0.20
Acute respiratory disease 28.2 20.3 -0.19 Malignant tumor of lung 3.4 2.0 -0.09
Attention deficit hyperactivity disorder 1.7 0.7 -0.09 Malignant tumor of urinary bladder 3.4 2.8 -0.04
Chronic liver disease 5.1 2.2 -0.16 Medication use
Chronic obstructive lung disease 17.1 9.6 -0.22 Agents acting on the renin-angiotensin system 77.8 73.8 -0.09
Crohn’s disease 0 0.6 0.11 Antibacterials for systemic use 62.4 47.6 -0.30
Dementia 17.9 12.3 -0.16 Antidepressants 70.1 58.7 -0.24
Depressive disorder 24.8 10.8 -0.37 Antiepileptics 43.6 36.4 -0.15
Diabetes mellitus 75.2 52.4 -0.49 Antiinflammatory and antirheumatic products 39.3 34.8 -0.09
Gastroesophageal reflux disease 26.5 14.1 -0.31 Antineoplastic agents 17.1 10.9 -0.18
Gastrointestinal hemorrhage 10.3 4.1 -0.24 Antipsoriatics 0.9 0.8 -0.01
Human immunodeficiency virus infection 0.9 0.8 -0.01 Antithrombotic agents 59.0 46.7 -0.25
Hyperlipidemia 39.3 23.7 -0.34 Beta blocking agents 74.4 77.5 0.07
Hypertensive disorder 14.5 4.4 -0.35 Calcium channel blockers 59.0 54.6 -0.09
Lesion of liver 7.7 2.7 -0.23 Diuretics 74.4 68.9 -0.12
Obesity 12.0 5.5 -0.23 Drugs for acid related disorders 65.0 45.4 -0.40
Osteoarthritis 61.5 38.3 -0.48 Drugs for obstructive airway diseases 51.3 39.8 -0.23
Pneumonia 6.8 5.2 -0.07 Drugs used in diabetes 66.7 58.2 -0.18
Psoriasis 3.4 1.5 -0.12 Immunosuppressants 4.3 4.7 0.02
Renal impairment 41.0 22.5 -0.41 Lipid modifying agents 81.2 76.2 -0.12
Rheumatoid arthritis 9.4 5.9 -0.13 Opioids 40.2 31.2 -0.19
Schizophrenia 6.8 6.0 -0.03 Psycholeptics 61.5 50.9 -0.22
Ulcerative colitis 0 0.4 0.09 Psychostimulants, agents used for adhd and nootropics 16.2 13.8 -0.07
Urinary tract infectious disease 27.4 19.9 -0.18 
## Event vs. All ##
Characteristic % (n = 731) % (n = 1,000) Std.Diff Characteristic % (n = 731) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 2.1 2.3 0.02
25 - 29 0.4 0.5 0.01 Visual system disorder 51.6 36.7 -0.30
30 - 34 0.7 1.0 0.03 Medical history: Cardiovascular disease
35 - 39 0.8 1.2 0.04 Atrial fibrillation 45.4 27.3 -0.38
40 - 44 1.2 1.4 0.01 Cerebrovascular disease 17.1 8.0 -0.28
45 - 49 2.7 1.3 -0.10 Coronary arteriosclerosis 48.0 31.7 -0.34
50 - 54 2.9 2.4 -0.03 Heart disease 83.0 56.9 -0.59
55 - 59 1.9 2.8 0.06 Heart failure 43.2 23.0 -0.44
60 - 64 3.4 4.3 0.05 Ischemic heart disease 24.9 11.8 -0.34
65 - 69 14.8 16.7 0.05 Peripheral vascular disease 47.1 25.1 -0.47
70 - 74 19.6 21.7 0.05 Pulmonary embolism 4.5 2.2 -0.13
75 - 79 15.7 16.4 0.02 Venous thrombosis 11.6 6.1 -0.20
80 - 84 17.0 14.1 -0.08 Medical history: Neoplasms
85 - 89 10.4 9.6 -0.03 Hematologic neoplasm 15.3 10.2 -0.15
90 - 94 4.9 4.2 -0.03 Malignant lymphoma 6.2 4.6 -0.07
95 - 99 2.7 2.0 -0.05 Malignant neoplasm of anorectum 3.8 1.5 -0.15
100 - 104 0.8 0.4 -0.05 Malignant neoplastic disease 44.6 28.8 -0.33
Gender: female 55.5 57.6 0.04 Malignant tumor of breast 6.7 2.5 -0.20
Medical history: General Malignant tumor of colon 6.3 3.8 -0.11
Acute respiratory disease 37.6 20.9 -0.37 Malignant tumor of lung 8.2 4.4 -0.16
Attention deficit hyperactivity disorder 0.4 0.4 0.00 Malignant tumor of urinary bladder 5.2 2.7 -0.13
Chronic liver disease 3.0 2.2 -0.05 Medication use
Chronic obstructive lung disease 23.8 10.1 -0.37 Agents acting on the renin-angiotensin system 43.6 0 -1.24
Crohn’s disease 0.7 0.7 0.00 Antibacterials for systemic use 36.7 0 -1.08
Dementia 18.9 10.9 -0.23 Antidepressants 42.3 0 -1.21
Depressive disorder 13.7 6.9 -0.22 Antiepileptics 26.4 0 -0.85
Diabetes mellitus 71.8 48.8 -0.48 Antiinflammatory and antirheumatic products 22.7 0 -0.77
Gastroesophageal reflux disease 22.7 14.4 -0.21 Antineoplastic agents 15.5 0 -0.60
Gastrointestinal hemorrhage 9.7 7.2 -0.09 Antipsoriatics 0.8 0 -0.13
Human immunodeficiency virus infection 0.8 0.4 -0.05 Antithrombotic agents 39.0 0 -1.13
Hyperlipidemia 36.3 25.2 -0.24 Beta blocking agents 40.2 0 -1.16
Hypertensive disorder 6.2 4.8 -0.06 Calcium channel blockers 32.4 0 -0.98
Lesion of liver 4.2 2.4 -0.10 Diuretics 43.1 0 -1.23
Obesity 10.1 4.1 -0.24 Drugs for acid related disorders 31.7 0 -0.96
Osteoarthritis 56.8 37.6 -0.39 Drugs for obstructive airway diseases 34.6 0 -1.03
Pneumonia 9.7 5.1 -0.18 Drugs used in diabetes 37.3 0 -1.09
Psoriasis 3.1 1.0 -0.15 Immunosuppressants 3.8 0 -0.28
Renal impairment 36.9 22.7 -0.32 Lipid modifying agents 46.5 0 -1.32
Rheumatoid arthritis 9.4 7.0 -0.09 Opioids 27.9 0 -0.88
Schizophrenia 8.9 3.7 -0.21 Psycholeptics 40.6 0 -1.17
Ulcerative colitis 0.7 0.5 -0.02 Psychostimulants, agents used for adhd and nootropics 11.9 0 -0.52
Urinary tract infectious disease 29.5 20.0 -0.22 
## Drug vs. All ##
Characteristic % (n = 731) % (n = 1,000) Std.Diff Characteristic % (n = 731) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 2.1 2.3 0.02
25 - 29 0.4 0.5 0.01 Visual system disorder 51.6 36.7 -0.30
30 - 34 0.7 1.0 0.03 Medical history: Cardiovascular disease
35 - 39 0.8 1.2 0.04 Atrial fibrillation 45.4 27.3 -0.38
40 - 44 1.2 1.4 0.01 Cerebrovascular disease 17.1 8.0 -0.28
45 - 49 2.7 1.3 -0.10 Coronary arteriosclerosis 48.0 31.7 -0.34
50 - 54 2.9 2.4 -0.03 Heart disease 83.0 56.9 -0.59
55 - 59 1.9 2.8 0.06 Heart failure 43.2 23.0 -0.44
60 - 64 3.4 4.3 0.05 Ischemic heart disease 24.9 11.8 -0.34
65 - 69 14.8 16.7 0.05 Peripheral vascular disease 47.1 25.1 -0.47
70 - 74 19.6 21.7 0.05 Pulmonary embolism 4.5 2.2 -0.13
75 - 79 15.7 16.4 0.02 Venous thrombosis 11.6 6.1 -0.20
80 - 84 17.0 14.1 -0.08 Medical history: Neoplasms
85 - 89 10.4 9.6 -0.03 Hematologic neoplasm 15.3 10.2 -0.15
90 - 94 4.9 4.2 -0.03 Malignant lymphoma 6.2 4.6 -0.07
95 - 99 2.7 2.0 -0.05 Malignant neoplasm of anorectum 3.8 1.5 -0.15
100 - 104 0.8 0.4 -0.05 Malignant neoplastic disease 44.6 28.8 -0.33
Gender: female 55.5 57.6 0.04 Malignant tumor of breast 6.7 2.5 -0.20
Medical history: General Malignant tumor of colon 6.3 3.8 -0.11
Acute respiratory disease 37.6 20.9 -0.37 Malignant tumor of lung 8.2 4.4 -0.16
Attention deficit hyperactivity disorder 0.4 0.4 0.00 Malignant tumor of urinary bladder 5.2 2.7 -0.13
Chronic liver disease 3.0 2.2 -0.05 Medication use
Chronic obstructive lung disease 23.8 10.1 -0.37 Agents acting on the renin-angiotensin system 43.6 0 -1.24
Crohn’s disease 0.7 0.7 0.00 Antibacterials for systemic use 36.7 0 -1.08
Dementia 18.9 10.9 -0.23 Antidepressants 42.3 0 -1.21
Depressive disorder 13.7 6.9 -0.22 Antiepileptics 26.4 0 -0.85
Diabetes mellitus 71.8 48.8 -0.48 Antiinflammatory and antirheumatic products 22.7 0 -0.77
Gastroesophageal reflux disease 22.7 14.4 -0.21 Antineoplastic agents 15.5 0 -0.60
Gastrointestinal hemorrhage 9.7 7.2 -0.09 Antipsoriatics 0.8 0 -0.13
Human immunodeficiency virus infection 0.8 0.4 -0.05 Antithrombotic agents 39.0 0 -1.13
Hyperlipidemia 36.3 25.2 -0.24 Beta blocking agents 40.2 0 -1.16
Hypertensive disorder 6.2 4.8 -0.06 Calcium channel blockers 32.4 0 -0.98
Lesion of liver 4.2 2.4 -0.10 Diuretics 43.1 0 -1.23
Obesity 10.1 4.1 -0.24 Drugs for acid related disorders 31.7 0 -0.96
Osteoarthritis 56.8 37.6 -0.39 Drugs for obstructive airway diseases 34.6 0 -1.03
Pneumonia 9.7 5.1 -0.18 Drugs used in diabetes 37.3 0 -1.09
Psoriasis 3.1 1.0 -0.15 Immunosuppressants 3.8 0 -0.28
Renal impairment 36.9 22.7 -0.32 Lipid modifying agents 46.5 0 -1.32
Rheumatoid arthritis 9.4 7.0 -0.09 Opioids 27.9 0 -0.88
Schizophrenia 8.9 3.7 -0.21 Psycholeptics 40.6 0 -1.17
Ulcerative colitis 0.7 0.5 -0.02 Psychostimulants, agents used for adhd and nootropics 11.9 0 -0.52
Urinary tract infectious disease 29.5 20.0 -0.22 
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
beta blocking agents 174
antithrombotic agents 138
cardiovascular system 116
alimentary tract and metabolism 112
nervous system 111
antiepileptics 102
respiratory system 97
lipid modifying agents 95
lipid modifying agents, plain 95
agents acting on the renin-angiotensin system 91
diuretics 87
psychoanaleptics 87
analgesics 86
hmg coa reductase inhibitors 85
antihistamines for systemic use 84
blood and blood forming organs 83
antidepressants 82
sensory organs 81
ophthalmologicals 80
all other therapeutic products 78
drugs used in diabetes 78
ace inhibitors, plain 77
ace inhibitors, plain 77
antiinfectives for systemic use 77
systemic hormonal preparations, excl. sex hormones and insulins 77
cond_180_days n_180_days
inflammation of specific body systems 99
arthropathy 97
heart disease 97
inflammation of specific body organs 92
pain 89
diabetes mellitus 88
pain finding at anatomical site 87
measurement finding outside reference range 83
type 2 diabetes mellitus 81
vascular disorder 81
pain of truncal structure 76
soft tissue lesion 74
degenerative disorder of musculoskeletal system 72
osteoarthritis 72
cardiac arrhythmia 68
neoplastic disease 66
musculoskeletal and connective tissue disorder 65
abnormal blood cell count 64
structural disorder of heart 64
measurement finding below reference range 63
anemia 61
arteriosclerotic vascular disease 61
cytopenia 61
erythropenia 61
hemoglobin level outside reference range 61